Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia
Authors' conclusion
In this pilot study, anamorelin did not significantly alter muscle mass; however, it may potentially improve lower extremity strength and bone formation in addition to increasing circulating IGF-1 levels in adults with OS. Further study of anamorelin in this population is warranted.
Study context
- Population
- Men and women aged ≥50 years with osteosarcopenia, Bone Metabolism Laboratory, USDA Nutrition Center at Tufts University
- Participants
- 26 men
- Comparison
- Anamorelin vs placebo for 1 year
- Primary endpoint
- Muscle mass (D3-creatine dilution), LBM and BMD (DXA), muscle strength, serum IGF-1, and bone turnover markers (P1NP, CTX)
- Follow-up
- 1 year
Methodological detailsplacebo-controlled, pilot study
- Placebo-controlled
- Pilot study
Primary result
As reported in the abstract
Muscle mass, LBM, strength, bone turnover, BMD
Knee flexion torque at 240°/s increased with anamorelin, P = .013
20%
Bone formation (P1NP) increased with anamorelin, P = .006
75%
Further findings
- Serum IGF-1 — Serum IGF-1 increase with anamorelin · increased by 50% with anamorelin; no change with placebo
- 50% · P = 0.0001 for group difference
Serum IGF-1
- Serum IGF-1 did not change with placebo
Original publication
Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia. J Clin Endocrinol Metab. Published 6 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →